Christopher Alafi - Intracellular Director
| ITCI Stock | USD 64.76 1.12 1.70% |
Director
Dr. Christopher D. Alafi Ph.D. is an Independent Director of IntraCellular Therapies, Inc. Dr. Alafi became a director of the Company following the Merger that occurred in August 2013 and has served on the board of directors of ITI since January 2013. Dr. Alafi was a General Partner of Alafi Capital Company, LLC, a VC firm and a principal stockholder of the Company, since 1995. He was previously a Physiology and Anatomy teacher at Santa Monica College, a visiting scholar in the Department of Chemistry at Stanford University and a researcher at DNAX. Dr. Alafi previously served as a director of ISTO Technologies, Coley Pharmaceutical Group, Inc., CyberGold, Inc. and Stereotaxis, Inc since 2014.
| Age | 54 |
| Tenure | 10 years |
| Address | 430 East 29th Street, New York, NY, United States, 10016 |
| Phone | 646 440 9333 |
| Web | https://www.intracellulartherapies.com |
Intracellular Management Efficiency
The company has return on total asset (ROA) of (0.1343) % which means that it has lost $0.1343 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2239) %, meaning that it created substantial loss on money invested by shareholders. Intracellular's management efficiency ratios could be used to measure how well Intracellular manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.2. The current Return On Capital Employed is estimated to decrease to -0.28. As of now, Intracellular's Non Currrent Assets Other are increasing as compared to previous years. The Intracellular's current Deferred Long Term Asset Charges is estimated to increase to about 635.1 K, while Total Assets are projected to decrease to under 410.9 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jerome Hauer | Emergent Biosolutions | 68 | |
| Gary Michael | PetIQ Inc | 77 | |
| George Morrow | Neurocrine Biosciences | 66 | |
| Sue Bailey | Emergent Biosolutions | 76 | |
| Corinne Nevinny | Neurocrine Biosciences | 57 | |
| Kathryn Zoon | Emergent Biosolutions | 71 | |
| Ronald Kennedy | PetIQ Inc | 71 | |
| Joseph Mollica | Neurocrine Biosciences | 59 | |
| Gary Lyons | Neurocrine Biosciences | 66 | |
| Will Santana | PetIQ Inc | 45 | |
| George Joulwan | Emergent Biosolutions | 80 | |
| Scott Huff | PetIQ Inc | 46 | |
| Alfred Sandrock | Neurocrine Biosciences | 60 | |
| Ronald Richard | Emergent Biosolutions | 64 | |
| Larry Bird | PetIQ Inc | 63 | |
| Louis Sullivan | Emergent Biosolutions | 86 | |
| Stephen Sherwin | Neurocrine Biosciences | 69 | |
| Mark First | PetIQ Inc | 53 | |
| Seamus Mulligan | Emergent Biosolutions | 58 | |
| James Clarke | PetIQ Inc | 45 | |
| Richard Pops | Neurocrine Biosciences | 56 | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.13 |
Intracellular Th Leadership Team
Elected by the shareholders, the Intracellular's board of directors comprises two types of representatives: Intracellular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intracellular. The board's role is to monitor Intracellular's management team and ensure that shareholders' interests are well served. Intracellular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intracellular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lawrence Wennogle, Vice President of Drug Discovery | ||
| Suresh Durgam, Senior Vice President Late Stage Clinical Development and Medical Affairs | ||
| Michael Rawlins, Director | ||
| Robert Nostrand, Independent Director | ||
| Richard Lerner, Director | ||
| Allen Fienberg, Co-Founder and VP of Bus. Devel. | ||
| Suresh MD, Executive Officer | ||
| Willie MD, Senior Development | ||
| Lawrence CPA, CFO, Finance | ||
| Kimberly Vanover, VP of Clinical Devel. | ||
| Michael Olchaskey, Senior Vice President Head of Regulatory Affairs | ||
| CPA CPA, CFO, Fin | ||
| Christopher Alafi, Director | ||
| Robert Davis, Senior Vice President and Chief Scientific Officer | ||
| Mark Neumann, Executive Vice President Chief Commercial Officer | ||
| Karen Esq, Senior Officer | ||
| Michael Halstead, Sr. VP, General Counsel and Secretary | ||
| Sharon Mates, Co-Founder, Chairman, CEO and Pres | ||
| Andrew Satlin, Executive Vice President and Chief Medical Officer | ||
| Michael JD, General VP | ||
| Juan Sanchez, Vice President - Corporate Communications and Investor Relations | ||
| Rory Riggs, Independent Director | ||
| John Bardi, Senior Vice President - Market Access, Policy and Government Affairs | ||
| Joel Marcus, Director | ||
| Lawrence Hineline, Vice President and CFO |
Intracellular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intracellular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 5.79 B | ||||
| Shares Outstanding | 96.81 M | ||||
| Shares Owned By Insiders | 2.51 % | ||||
| Shares Owned By Institutions | 99.04 % | ||||
| Number Of Shares Shorted | 3.47 M | ||||
| Price To Earning | (6.56) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Intracellular Th information on this page should be used as a complementary analysis to other Intracellular's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Intracellular Stock analysis
When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is Intracellular's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Revenue Per Share 4.843 | Quarterly Revenue Growth 0.503 | Return On Assets (0.13) | Return On Equity (0.22) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.